Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laura Bounaix1, Mohammed Bendouda1, Jacques-Olivier Bay1

  • 1Clermont Université; Clermont Université, université d'Auvergne, EA7283, CIC501, BP 10448, F-63000 Clermont-Ferrand, France.

Bulletin Du Cancer
|January 7, 2017
PubMed
Summary

Anti-PD-1 antibodies show promise in treating lymphoid cancers. This review covers current clinical results and future directions for PD-1 blockade therapy in lymphoid neoplasms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Bone marrow transplantation·2026
Same author

Characterisation of the Novel HLA-C*05:315 Allele by Sequencing-Based Typing.

HLA·2026
Same author

Characterisation of the Novel HLA-B*35:08:18 Allele by Sequencing-Based Typing.

HLA·2026

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Immune checkpoint blockade is a developing area in oncology.
  • PD-1 blockade has shown anti-tumor efficacy in certain lymphoid malignancies.

Purpose of the Study:

  • To review the clinical efficacy of anti-PD-1 antibodies in lymphoid neoplasms.
  • To discuss the future development of PD-1 inhibitors in hematologic malignancies.

Main Methods:

  • Literature review of clinical studies on PD-1 inhibitors.
  • Analysis of current data on PD-1 blockade in lymphoid neoplasms.

Main Results:

  • PD-1 inhibitors demonstrate clinical efficacy in specific lymphoid malignancies.
  • Evidence supports the anti-tumor activity of PD-1 blockade in hematology.

Conclusions:

  • Anti-PD-1 antibodies are a promising therapeutic strategy for lymphoid neoplasms.
  • Further research is warranted to optimize PD-1 inhibitor development in hematologic cancers.
Keywords:
LymphomaLymphomeNivolumabPD-1

Related Experiment Videos